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ABSTRACT
Multiple myeloma (MM) is a clonal plasma cell
disorder defined by bone marrow infiltration
and osteolytic bone lesions and is the second
most common hematologic malignancy after
non-Hodgkin lymphoma. The landscape of MM
treatment was transformed at the dawn of the
twenty-first century by the introduction of
novel agents including proteasome inhibitors
(bortezomib) and immunomodulatory drugs
(thalidomide, lenalidomide), which have
prolonged the survival of MM patients. The
recently revised International Myeloma
Working Group diagnostic criteria for MM
added validated biomarkers (clonal bone
marrow plasma cell C60%,
involved:uninvolved serum free light chain
ratio C100, or [1 focal lesion on magnetic
resonance imaging) to identify near inevitable
progression to symptomatic MM requiring
therapy. In addition, the definition of
myeloma-defining CRAB features
(hypercalcemia, renal failure, anemia, and
bone lesions) has been refined based on
advances in imaging and laboratory
techniques since the 2003 IMWG consensus.
Despite expanded treatment options, MM
remains an incurable disease. Drug resistance
and clonal evolution remain problematic, and
novel therapeutic agents are needed. New
approaches to myeloma treatment include
anti-CD38 antibodies, next generation
proteasome inhibitors, epigenetic modulation
with histone deacetylase inhibitors, and
targeting the tumor microenvironment. In this
article, the diagnosis, staging, and prognostic
stratification of newly diagnosed MM will be
reviewed. Clinical data pertaining to the
emerging targeted agents will be discussed,
and a suggested framework for integration of
these new therapeutic options will be provided.
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INTRODUCTION
Multiple myeloma (MM) is the second most
common hematologic malignancy and is
characterized by the presence of a monoclonal
protein detectable in the blood and/or urine,
clonal plasma cell involvement of the bone
marrow, and lytic bone lesions, anemia, renal
insufficiency, and hypercalcemia. In 2014, an
estimated 26,850 new cases of MM were
diagnosed and were responsible for 11,240
deaths [1]. Monoclonal gammopathy of
undetermined significance (MGUS) precedes
MM in virtually all cases [2]. The
immunomodulatory drugs (IMiDs)
thalidomide and lenalidomide and the
proteasome inhibitors bortezomib and
carfilzomib have led to substantial
improvement in patient outcomes. Median
overall survival (OS) in patients diagnosed
after the year 2000 has more than doubled
compared to patients diagnosed prior to the era
of novel agents [3]. In this review, diagnosis and
risk stratification, recommendations for initial
and subsequent therapy, and a discussion
regarding emerging therapies for MM will be
provided. This review is based on previously
conducted studies and does not involve any
new studies of human or animal subjects
performed by any of the authors.
DIAGNOSIS
A monoclonal protein may be discovered in the
serum or urine following diagnostic testing for a
variety of conditions including the evaluation
of anemia, renal impairment, hypercalcemia,
musculoskeletal pain, or neurologic conditions.
MGUS and smoldering MM must be
differentiated from MM necessitating
treatment. Pathologic examination of the bone
marrow with aspirate and biopsy are essential
for making the diagnosis of MM, which is
defined by the presence of C10% clonal bone
marrow plasma cells (BMPCs) with one or more
myeloma-defining features [4]. The revised
International Myeloma Working Group
diagnostic criteria for MM incorporated the
validated biomarkers of BMPCs C60%,
involved:uninvolved serum free light chain
(FLC) ratio of C100, or [1 focal lesion on
magnetic resonance imaging (MRI) spine as
myeloma-defining events, and patients with
these features are no longer considered
smoldering MM [4]. Due to the greater than
80 % risk of these patients developing
symptomatic disease within 2 years without
therapy, treatment may now be offered prior
to the onset of CRAB features (hypercalcemia,
renal failure, anemia, and bone lesions). CRAB
criteria have also been updated recognizing the
advances in the detection of bone and
extramedullary lesions by computed
tomography (CT) and positron emission
tomography (PET)/CT as well as better
estimation of renal impairment by
measurement of creatinine clearance in
addition to serum creatinine.
A diagnostic panel of serum protein
electrophoresis (SPEP), serum immunofixation
(IFE), and the serum FLC assay should be
obtained when MM is suspected. The serum
FLC assay quantifies kappa and lambda light
chains circulating unbound from the heavy
chain and detects a clonal process by the
alteration of the kappa/lambda ratio. In a
study involving 1877 samples, sensitivity for
detection of monoclonal proteins in MM was
87.6% for SPEP, 94.4% for serum IFE, and 98.6%
for serum FLC, with a combined 100%
diagnostic sensitivity [5]. If a patient is
diagnosed with a plasma cell disorder by
initial screening, then a 24-h urine protein
electrophoresis (UPEP) and immunofixation
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should be obtained. With the use of the serum
FLC along with SPEP, IFE, and UPEP, only
approximately 2% of patients are determined
to have non-secretory disease [6].
Multiparameter flow cytometry has become
a valuable addition to the morphologic
assessment of the bone marrow and may
provide additional prognostic information.
Immunophenotyping allows precise separation
of aberrant plasma cells (typically CD19, CD27,
and CD45-negative, CD56-positive) from
normal plasma cells (CD19 and CD45-positive,
CD56-negative) [7, 8]. Paiva et al. [9] reported
that newly diagnosed MM patients with B15%
aberrant BMPCs had a progression-free survival
(PFS) of 43 vs. 36 months (P = 0.003) and OS of
97 vs. 54 months (P\0.001). Quantification of
circulating clonal plasma cells by flow
cytometry is also a useful prognostic marker,
and the presence of [400 circulating plasma
cells shortened time to next treatment and
median OS (14 vs. 26 months; 32 months vs.
not reached; P\0.001) [10]. Plasma cell
proliferation may also be precisely evaluated
by flow cytometry and has replaced the
slide-based plasma cell labeling index (PCLI)
[11]. Aspirate samples from the first pull should
be used for plasma cell quantification to
minimize sampling error.
The whole-body skeletal survey by
conventional radiography (WBXR) has been
utilized for decades in the evaluation for
osteolytic lesions; however, more advanced
imaging technologies including whole-body
CT, MRI, and PET/CT are being increasingly
utilized to detect bone and extramedullary
disease. In 2009, the IMWG recommended the
continued use of WBXR despite its limitations
in detecting spine and pelvic bone
involvement. Spine and pelvic or whole-body
MRIs are suggested in symptomatic patients if
WBXR is negative as well as those with
compression fractures to exclude spinal cord
compression [12]. In patients with smoldering
MM or solitary plasmacytoma, 18F-FDG PET/CT
or axial MRI should be performed to evaluate
for the presence of[1 focal lesion as results may
influence management in one-third of patients
[13, 14]. To compare the performance of axial
MRI and WBXR, 611 myeloma patients
underwent both studies. In 267 patients with
normal WBXR, 52% had focal lesions on MRI,
whereas 20% of the 160 patients with normal
MRI results had abnormal WBXR. Twenty-one
percent of patients had no focal lesions by
either technique, whereas 51% had lesions on
both MRI and WBXR. Importantly, MRI was
superior in detection of lesions in the spine
(78% vs. 16%; P\0.001), pelvis (64% vs. 28%;





Despite therapeutic advances, outcomes remain
heterogeneous with an approximate 10%
mortality rate within the first year following
diagnosis, while one-third of patients diagnosed
earlier than age 65 years live beyond a decade
[15]. The Durie Salmon Staging system and
International Staging System (ISS) were
developed to classify patients into risk groups
and provide prognostic information using
readily available clinical information. The ISS
was developed from data on patient outcomes
from 1981 to 2002 in over 10,000 patients and
consists of three stages: stage I
(b-2-microglobulin \3.5 mg/dl and albumin
C3.5 g/dl; median OS 62 months), stage II
(neither stage I or II; median OS 44 months),
and stage III (b-2-microglobulin C5.5 g/dl;
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median OS 29 months) [16]. The ISS has also
been validated in patients treated with novel
agents, and 5-year survival in stages I, II, and III
patients was significantly different between
groups at 66 %, 45 %, and 18 %, respectively
(P\0.001) [17].
The development of interphase fluorescent
in situ hybridization (FISH) to detect recurrent
cytogenetic abnormalities has been a critical
factor in identifying variability intrinsic to the
plasma cell clone [18]. Translocations involving
the immunoglobulin heavy-chain locus (IgH;
14q32) and hyperdiploidy of odd-numbered
chromosomes are commonly detected by FISH
[19, 20]. Monosomy of chromosome 13 or 17,
deletions involving chromosomes 1, 13, or 17,
and amplification of chromosome 1q are also
frequent findings. Recurrent chromosomal
translocations have both prognostic and
therapeutic implications and have led to the
development of risk-adapted treatment
strategies [21]. Institutionally, we have
developed a FISH-based stratification model
known as mSMART (Mayo Stratification of
Myeloma and Risk-Adapted Therapy) that aims
to individualize therapy based on tumor biology
and patient-related factors. The mSMART
classification stratifies patients into three risk
groups: high risk [deletion 17p, t(14;16),
t(14;20) or high risk gene expression profile];
intermediate risk [t(4;14), 1q amplification,
metaphase deletion 13, or high plasma cell
proliferative rate S-phase]; or standard risk
[hyperdiploid, t(11;14), or t(6;14)] (Table 1).
Traditionally, median OS for high,
intermediate, and standard risk disease was
less than 3 years, 4–5 years, and 8–10 years,
respectively [21, 22]. In an effort to improve
outcomes for high-risk patients, combination
induction therapy with both an IMiD and
proteasome inhibitor (bortezomib,
lenalidomide, dexamethasone; VRd) followed
by bortezomib maintenance is recommended.
In standard risk trisomy-only patients, an
oral-based induction with lenalidomide/
dexamethasone (Rd) until progression is
suggested, with consideration of delayed
autologous stem cell transplantation (ASCT) in
eligible patients. For intermediate or standard
risk patients, weekly VCd (bortezomib,
cyclophosphamide, dexamethasone; CyBorD)
is recommended, followed by ASCT and
varying post-transplant consolidation and
maintenance strategies based on risk group.
Beyond detection of primary genetic
alterations by FISH, gene expression profiling
(GEP), single nucleotide polymorphism (SNP)
arrays, and next generation sequencing have
confirmed significant clonal heterogeneity with
few recurrent driver mutations [23].
Whole-exome sequencing of three myeloma
patient cohorts demonstrated subclonal KRAS,
NRAS, and BRAF mutations in one-third of
patients and significant heterogeneous
subclonal structure [24]. At present, clear
biologic subgroups and predictive markers of
therapeutic response have yet to be discovered.
TREATMENT OF NEWLY
DIAGNOSED MM
Critical factors to be considered during the
initial evaluation of newly diagnosed MM are
the performance status, age, medical
comorbidities, and preferences of the patient
in addition to the intrinsic tumor biology. ASCT
should be considered for all eligible patients
younger than age 70 years with good
performance status and absence of significant
comorbidities. Multiple randomized studies
performed prior to the development of IMiDs
and proteasome inhibitors demonstrated a
survival advantage with ASCT compared to
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nonintensive therapy [25, 26]. Induction
therapy utilizing novel agents results in higher
response rates post-induction and
post-transplantation when compared with
VAD (vincristine, doxorubicin,
dexamethasone) [27]. VAD achieved at least
partial response (PR) in 50% of patients,
complete response (CR) in\10%, and CVGPR
in 15% [28]. Thalidomide-dexamethasone (TD)
improved the post-induction objective response
rate (ORR; CPR) to 75% of patients, however,
achieved CR in only 10% and CVGPR in less
than 20% of patients. TD has now been replaced
by more effective and better tolerated
lenalidomide-based regimens. Lenalidomide
and bortezomib are now routinely
incorporated into pre-ASCT induction
regimens and do not interfere with adequate
stem cell collection. More recently, Palumbo
et al. [29] compared ASCT to melphalan,
prednisone, and lenalidomide (MPR)
consolidation therapy following four cycles of
induction therapy with
lenalidomide-dexamethasone (Rd). Both PFS
and OS were significantly better in the ASCT
group [median PFS 43.0 vs. 22.4 months, hazard
ratio (HR) 0.44; P\0.001 and 4-year OS 82% vs.
65%, HR 0.55; P = 0.02]. The rising number of
effective and well-tolerated treatment options
in recent years has led to a debate over early
versus delayed ASCT, and two large intergroup
studies have been initiated to examine this
issue. In a review of 290 newly diagnosed MM
patients treated at the Mayo Clinic with
IMiD-based induction, there was no difference
in time to progression or 4-year OS between the
early or delayed ASCT groups [30].
In the USA, ASCT with high-dose melphalan
may be performed safely in very fit patients
[70 years old with advances in supportive care;
therefore, age alone should not be the primary
limiting factor in patient selection. Patients
above age 65 years with good performance
status who are not felt to be suitable for
melphalan 200 mg/m2 may still benefit from
reduced intensity autologous transplantation
with melphalan 100 mg/m2. The IFM 99-06
trial-randomized patients aged 65–75 years to
treatment with melphalan and prednisone
(MP), melphalan and prednisone plus
thalidomide (MPT), or VAD induction
followed by ASCT with reduced intensity
melphalan 100 mg/m2 (MEL100) [31]. Median
OS was superior in the MPT group at 51.6 vs.
33.2 months for MP and 38.3 months for
MEL100; however, the VAD induction arm
may have contributed to inferior outcomes in
the transplant arm. Reduced intensity ASCT was
again evaluated using a more active induction
regimen of bortezomib plus liposomal
doxorubicin and dexamethasone (PAD) in
patients aged 65–75 years followed by tandem
MEL100 and lenalidomide plus prednisone
consolidation. The median PFS was 48 months
and 5-year OS was 63 %, demonstrating
bortezomib-based induction followed by
reduced ASCT may be an option in select
elderly patients [32].
Table 1 Risk stratiﬁcation of multiple myeloma by
cytogenetic abnormalities
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Significant variability exists in the choice of
primary therapy for both transplant and
non-transplant candidates, and head-to-head
comparisons of the commonly used triplet
regimens of bortezomib, lenalidomide,
dexamethasone (VRd) and bortezomib,
cyclophosphamide, dexamethasone (VCd or
CyBorD) are lacking. Table 2 lists commonly
used frontline regimens, their respective
response rates, and available survival data for
transplant-eligible and transplant-ineligible
patients. Data pertaining to Rd and the triplet
induction regimens of VTD, VCD, VRD, and
KRD (carfilzomib, lenalidomide,
dexamethasone) are further described below.
A decision regarding the frontline
management of elderly patients not eligible
for transplantation must balance adequate
disease control while avoiding excess
treatment-related toxicities. The VISTA trial, a
phase III comparison of VMP to MP in elderly
newly diagnosed MM patients, demonstrated a
significant improvement in time to next
treatment (31 vs. 21 months) and median OS
(56 vs. 43 months) with the addition of
bortezomib [33, 34]. Subsequent modifications
to the VMP regimen have reduced
treatment-related toxicities by moving to once
weekly dosing and subcutaneous rather than
intravenous administration of bortezomib.
Bortezomib, thalidomide, and prednisone
(VTP) were compared to VMP in an effort to
reduce toxicities; however, higher rates of
treatment discontinuation and serious adverse
events occurred in the VTP group without
improvement in efficacy [35]. The UPFRONT
phase III trial compared bortezomib/
dexamethasone (VD), bortezomib/
dexamethasone plus thalidomide (VTD), and
VMP in transplant-ineligible patients treated in
the US community practice setting, and the
triplet combinations of VTD and VMP did not
offer a significant progression-free or OS benefit
[36]. In fit elderly patients, the VCD and VRD
regimens have been adopted based on phase II
studies and are often substituted for VMP and
VTD, respectively. In less fit elderly patients, less
intensive therapy with doublet combinations
(VD or Rd) and dose reductions are
recommended. Continuous lenalidomide/
dexamethasone (Rd) until progression was
demonstrated to be superior in PFS and OS
compared to fixed duration Rd for 18 cycles and
MPT for 12 cycles and may be considered a new
standard of care for newly diagnosed
transplant-ineligible patients [37]. The routine
use of maintenance therapy following fixed
duration first-line treatment has not
demonstrated an OS benefit consistently and
is not recommended in standard practice
outside of a clinical trial.
Lenalidomide/Dexamethasone (Rd)
Lenalidomide is an analog of thalidomide with
more potent anti-MM activity and ability to
stimulate T cell proliferation, interleukin (IL)-2,
and interferon-c without the problematic
somnolence, constipation, and neuropathy
that limited thalidomide [38]. The mechanism
of IMiDs has been elucidated following the
identification of the cereblon protein (CRBN) as
the target of thalidomide [39]. IMiDs bind to
CRBN and cause degradation of transcription
factors Ikaros and Aiolos, resulting in
downregulation of IRF4 and Myc and
cytotoxicity to myeloma cells [40, 41].
Significant clinical activity was demonstrated
in a phase II study of lenalidomide plus
high-dose dexamethasone. An ORR of 91%
was achieved with CVGPR of 32% and CR rate
of 6% [42]. Subsequently, lenalidomide plus
weekly dexamethasone (low dose) was
compared to lenalidomide plus high-dose
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dexamethasone [43]. At the 1-year interim
analysis, OS was 96% in the low-dose arm
compared to 87% in the high-dose
dexamethasone arm, and the trial was stopped
early. Grade 3 or higher toxicities were more
frequent with high-dose dexamethasone (DVT
or PE in 26%, 16% grade 3 infection, 15%
fatigue, 11% non-neuropathic weakness, 11%
hyperglycemia). Lenalidomide with low-dose
dexamethasone (Rd) has since become a
Table 2 Primary induction regimens for newly diagnosed transplant-eligible and transplant-ineligible multiple myeloma
Trial Regimen CR (%) ‡VGPR (%) ORR (%) PFS OS
Transplant-eligible patients
Reeder et al. [93] VCD 22 67 75 1 year 93% 1 year 100%
Richardson et al. [56] VRD 37 74 100 18 months 75% 18 months 97%
Rajkumar et al. [43] Rd 4 40 70 25.3 months 1 year 96%, 2 years 87%
Moreau et al. [49] VTD 13 49 88 NA NA
Jakubowiak et al. [59] KRd 45 88 100 24 months 92% NA
Kumar et al. [53] VDRC 25 58 88 1 year 86% 1 year 92%
Jakubowiak et al. [94] VDD 38 58 85 1 year 93% 1 year 97.5%
Transplant-ineligible patients
Facon et al. [31] MPT 13 47 76 27.5 months 51.6 months
MP 2 7 35 17.8 months 33.2 months
Palumbo et al. [95] MPR-R 33 33 77 31 months 3 years 70%
MPR 33 33 68 14 months 3 years 62%
MP 12 12 50 13 months 3 years 66%
San Miguel et al. [96] VMP 30 41 71 24 months Median NR
MP 4 8 35 17 months 43 months
Rajkumar et al. [43] Rd 4 40 70 25.3 months 2 years 87%
RD 5 50 81 19.1 months 2 years 75%
Niesvizky et al. [36] VD 3 37 73 14.7 months 49.8 months
VTD 4 51 80 15.4 months 51.5 months
VMP 3 41 70 17.3 months 53.1 months
Palumbo et al. [97] VMPT-VT 38 59 89 3-year PFS 56% 3-year OS 89%
VMP 24 50 81 3-year PFS 33% 3-year OS 87%
CR complete response, KRd carﬁlzomib, lenalidomide, dexamethasone, MPT melphalan, prednisone, thalidomide, MRP
melphalan, prednisone, lenalidomide, NR not reached, ORR objective response rate, OS overall survival, PFS
progression-free survival, PR partial response, Rd lenalidomide dexamethasone, VCD bortezomib, cyclophosphamide,
dexamethasone, Vd bortezomib, dexamethasone, VDD bortezomib, pegylated liposomal doxorubicin, dexamethasone,
VDRC bortezomib, dexamethasone, lenalidomide, cyclophosphamide, VGPR very good partial response, VMP bortezomib,
melphalan, prednisone VRD bortezomib, lenalidomide, dexamethasone, VTD bortezomib, thalidomide, dexamethasone
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standard initial therapy. Thromboprophylaxis
with aspirin, warfarin, or low-molecular-weight
heparin is essential for all patients treated with
IMiDs to reduce the near 25% incidence of
thrombotic complications in patients without
prophylaxis [44].
Fixed duration therapy has been a mainstay
for decades; however, this paradigm is also
changing. The FIRST trial randomized
transplant-ineligible patients to either
lenalidomide/dexamethasone for 18 cycles,
until disease progression, or MPT for 18 cycles
[37]. Median PFS was superior with continuous
Rd at 25.5 months (HR 0.72; P\0.001) versus
fixed duration Rd (PFS 20.7 months) or MPT
(PFS 21.2 months). The safety profile of Rd was
also more favorable than MPT with fewer grade
C3 hematologic toxicities, significantly less
neuropathy, and fewer second primary cancers.
Bortezomib, Thalidomide,
and Dexamethasone (VTD)
Significantly higher response rates during
induction therapy for untreated MM were
achieved with the introduction of bortezomib/
dexamethasone (VD) [45] and thalidomide/
dexamethasone (TD) [28, 46] compared to
VAD. The triplet combination of bortezomib,
thalidomide, and dexamethasone (VTD) was
the first regimen to utilize both an IMiD and a
proteasome inhibitor. A GIMEMA phase III
study of 474 patients compared VTD
(bortezomib 1.3 mg/m2 IV on days 1, 4, 8, 11;
thalidomide 200 mg daily; dexamethasone
320 mg per 21 day cycle) to TD [47].
Post-induction rates of VGPR or better were
significantly higher with VTD compared to TD
(62% vs. 28%; P\0.0001), and PFS at 3 years
was also improved (68% vs. 56%). The improved
depth of response was offset by a higher
incidence of grade C3 peripheral neuropathy
in the VTD arm compared to TD (10% vs. 2%;
P = 0.0004), and there was no difference in OS
at 3 years (86% vs. 84%). The PETHEMA/GEM
phase III study compared VTD to TD and
alternating cycles of VBMCP/VBAD and
demonstrated similar findings as patients
treated with VTD achieved higher response
rates compared to TD and VBMCP/VBAD
(CVGPR in 60% vs. 29% vs. 36%); however,
VTD resulted in significantly higher rates of
peripheral neuropathy [48]. In the VTD arm,
treatment-emergent grade C3 peripheral
neuropathy developed in 14% compared to
5% with TD, and 46% of patients in the VTD
arm developed grade 2 peripheral neuropathy.
Subsequently, Moreau et al. [49] compared
reduced-dose bortezomib and thalidomide plus
dexamethasone (vtD) to VD and demonstrated
improved efficacy with use of vtD (CVGPR 49%
vs. 36%; P = 0.05) with lower rates of peripheral
neuropathy (grade 1–4 53% vs. 70%; P = 0.01).
Cyclophosphamide, Bortezomib,
and Dexamethasone (VCD or CyBorD)
Preclinical data suggest synergistic anti-MM
activity with concurrent proteasome inhibition
and chemotherapeutic agents such as
doxorubicin and alkylating agents to induce
DNA damage [50]. In a phase II trial of 33
patients with untreated MM, bortezomib
1.3 mg/m2 intravenously on days 1, 4, 8, and
11, cyclophosphamide 300 mg/m2 orally once
weekly, and high-dose dexamethasone were
given each 28 day cycle. After four cycles,
patients who achieved an ORR of 88% and
61% had a VGPR or better. A second cohort of
30 patients was treated with a modified
schedule using the same cyclophosphamide
dose, weekly bortezomib 1.5 mg/m2, and
weekly dexamethasone 40 mg [51]. The
modified CyBorD regimen had fewer grade 3/4
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adverse events (37%/3% vs. 48%/12%) and
fewer required dose reductions of bortezomib
and dexamethasone. Subcutaneous bortezomib
administration has also replaced intravenous
infusion because of the reduced incidence of
peripheral neuropathy with this route of
administration [52].
In the EVOLUTION study, the efficacy and
tolerability of combining bortezomib,
cyclophosphamide, lenalidomide, and
dexamethasone (VDCR) was studied in
comparison to VDR (bortezomib,
dexamethasone, lenalidomide) and VDC in
two separate dosing schemes [53]. VDCR
demonstrated similar activity to triplet
combinations with a VGPR or better rate of
58% and CR rate of 25%; however, grade 3
hematologic toxicity was significantly higher.
VDR and VCD were recommended for further
comparative testing.
The VCd combination does not interfere
with stem cell harvest and is an effective
pretransplant induction regimen. A
retrospective comparison of VCD and VTD as
pretransplant induction therapy reported VTD
may achieve higher rates of CVGPR and CR and
be better tolerated compared to VCD; however,
questions about the methodology of the study
have been raised [54, 55]. The ongoing IFM
2013-04 randomized study is comparing VTD
versus VCD for four cycles prior to ASCT in
order to compare post-induction response rates
and safety of the two commonly used regimens.
Bortezomib, Lenalidomide,
and Dexamethasone (VRD)
Bortezomib, lenalidomide, and dexamethasone
(VRD) were combined with the aim of achieving
the higher rates of response observed with VTD
while improving upon the safety profile. In a
phase I/II study, the regimen of bortezomib
1.3 mg/m2 on days 1, 4, 8, and 11; lenalidomide
25 mg on days 1–14; and dexamethasone 20
mg days 1, 2, 4, 5, 8, 9, 11, and 12 per 21 day
cycle was selected for the phase II component
[56]. In this cohort of 35 patients, 37% had a
CR, 74% had CVGPR, and all patients had an
objective response. The most common adverse
events were peripheral neuropathy in 80% (2%
grade 3), fatigue (64%), constipation (61%),
myalgia (44%), rash (36%), diarrhea (35%),
nausea (32%), neuropathic pain (32%), and
insomnia (30%).
The combination of an IMiD and a
proteasome inhibitor leads a greater depth of
response compared to historic regimens, but at
a higher rate of toxicity and cost. Prospective
data on whether achieving the surrogate
endpoints of CR or CVGPR result in improved
OS are lacking; however, retrospective studies
have attempted to answer this question. In
transplant-ineligible patients treated with MP,
MPT, VMP, or VMPT, PFS at 3 years was 67% in
those who achieved a CR versus 27% in those
without a CR [57]. Three-year OS was 91% in
the group that obtained a CR versus 67% in
those with a VGPR or PR.
Carfilzomib, Lenalidomide,
and Dexamethasone (KRd)
Newer frontline regimens substituting
carfilzomib for bortezomib have also been
studied. Carfilzomib is a second-generation
proteasome inhibitor with distinct chemical
properties from bortezomib with highly
chymotrypsin-specific irreversible proteasome
inhibition [58]. Twice-weekly carfilzomib
(36 mg/m2 based on dose escalation) was
combined with lenalidomide 25 mg days 1–21
plus weekly dexamethasone at 40 mg in a phase
I/II study of newly diagnosed MM patients [59].
At the 36 mg/m2 dose level, 39% achieved
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stringent CR, 55% near CR, 72% VGPR or better,
and 97% of patients had an objective response.
The incidence of peripheral neuropathy
compared to VRD was lower at 23% and was
limited to grade 1 (17%) and grade 2 (6%).
Treatment-related non-hematologic adverse
events were generally mild to moderate and
included hyperglycemia in 72% (23% grade
3/4), edema (47%), hypophosphatemia (45%),
fatigue (38%), muscle cramping (32%), rash
(28%), elevated liver function tests (28%),
diarrhea (26%), dyspnea (15%), DVT (11%),
pulmonary embolism (6%), and nausea (13%).
Grade 3/4 thrombocytopenia, anemia, and
neutropenia developed in approximately 20%
of patients. The ECOG E1A11 ENDURANCE
study is currently enrolling patients to compare
the efficacy and safety of KRd to VRD and will
also analyze the role of limited versus indefinite




Despite highly active combination regimens
with novel agents, high-dose melphalan with
stem cell transplant and an increasing use of
consolidation and maintenance therapy, MM
remains an incurable disease in the vast
majority of patients, and subsequent lines of
therapy are required to address disease relapse.
The treatment of patients with dual-refractory
disease to lenalidomide and bortezomib
remains challenging, as median survival was
9 months in this population prior to the
introduction of carfilzomib and pomalidomide
[60]. Given the abundance of available
treatment options for relapsed disease, patient
factors (performance status, renal function,
neuropathy), tumor biology (risk status, pace
of relapse, presence of extramedullary disease or
plasma cell leukemia), and treatment-related
factors (duration of response to prior therapies,
exposure to major classes of therapies including
IMiDs, proteasome inhibitors, and alkylating
agents) need to be considered before selecting a
salvage therapy [61]. Close observation without
treatment is reasonable in the case of indolent
biochemical progression, whereas patients with
rapid relapse and evidence of end-organ
dysfunction benefit from combination therapy
utilizing multiple novel agents. Combination
therapy utilizing multiple mechanisms of
action to overcome drug resistance and clonal
heterogeneity is being increasingly utilized. The
duration of response to each subsequent line of
therapy decreases consistently [62]; therefore,
retreatment with a prior regimen may be
considered if remission off therapy has lasted
more than 6 months. This approach is
supported by data from the VISTA [63] and
RETRIEVE [64] studies, which demonstrated
ORR in 40–60% of patients upon retreatment
with bortezomib or lenalidomide.
Transplant-eligible patients who delayed ASCT
initially are recommended to undergo ASCT
upon first relapse. Relapse following initial
treatment with an IMiD based regimen (Rd or
VRd) may be treated with VCd, KRd, or
pomalidomide/dexamethasone. Several
promising combination regimens using next
generation novel agents are undergoing clinical
testing, and available outcome data using these
regimens are listed in Table 3.
Next Generation Proteasome Inhibitors
The proteasome is a key structure within the
nucleus and cytoplasm of eukaryotic cells that
degrades ubiquinated proteins and is involved
in cell homeostasis [65]. The
ubiquitin-proteasome pathway is a rational
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therapeutic target as proteasome inhibition
results in accumulation of misfolded proteins,
endoplasmic reticulum stress, and induction of
apoptosis [66]. Bortezomib was the first
compound to attain regulatory approval and
was initially used as a single-agent in relapsed/
refractory disease but now is a fundamental
component of several combination therapies.
Bortezomib is a dipeptide boronic acid and
reversible inhibitor of the 20S proteasome
primarily at the chymotrypsin-like and
caspase-like active sites [67]. Following the
success of bortezomib, several other
compounds with unique chemical
characteristics have entered clinical testing in
an attempt to overcome bortezomib resistance
as well as to improve the safety profile of
proteasome inhibition.
Carfilzomib has several unique chemical
properties compared to bortezomib.
Carfilzomib is a peptide epoxyketyone that is
an irreversible, highly selective inhibitor of
chymotrypsin-like activity with fewer
off-target effects on non-proteasomal targets
and significantly less neurotoxicity compared
to bortezomib [58]. In the PX-171-004 phase II
study, relapsed/refractory bortezomib-naive
patients received either carfilzomib 20 mg/m2
for 12 cycles or 20 mg/m2 in cycle 1 then 27 mg/
m2 in cycles 2–12 [68]. The ORR was higher in
the 20/27-mg/m2 group compared to the
20-mg/m2 group (52.2% vs. 42.4%), and the
incidence of treatment-emergent peripheral
neuropathy was low (17.1% overall) with no
treatment discontinuations due to neuropathy.
Patients with heavily pretreated MM including
bortezomib-treatment were enrolled in the
PX-171-003-A1 phase II study of single-agent
carfilzomib and were treated with 20 mg/m2
twice weekly 3 weeks out of 4 during cycle 1
then 27 mg/m2 thereafter. In this study, the
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3.7 months and median duration of response of
7.8 months [69]. Based on the encouraging
single-agent activity and favorable toxicity
profile, carfilzomib has been incorporated into
several combination regimens. Carfilzomib,
lenalidomide, and dexamethasone (KRd) were
compared to Rd in the ASPIRE study and
demonstrated a significant improvement in
the PFS (26.3 vs. 17.6 months) and CR rate
(31.8 % vs. 9.3 %). KRd compares favorably in
both efficacy and tolerability to VTD (median
PFS 19.5 months; 29 % rate of grade
C3 peripheral neuropathy) [70]. In a phase II
study of relapsed/refractory MM patients treated
with VRd, median PFS was 9.5 months with a
CR rate of 11 %. The incidence of
treatment-related peripheral neuropathy was
higher at 53 % with VRd compared to 17 % in
the KRd ASPIRE study.
Ixazomib (MLN9708) is a second-generation,
orally bioavailable 20S proteasome inhibitor
with improved tissue penetration and
antitumor activity [71]. Ixazomib has
significant single-agent activity even with
prior bortezomib and carfilzomib exposure,
and an ORR of 27 % was seen in patients
treated at the maximum tolerated dose [72].
The phase III TOURMALINE-MM1 study
compared ixazomib 4 mg PO on days 1, 8, and
15 plus lenalidomide and dexamethasone to Rd
in patients with relapsed/refractory MM. The
primary endpoint of improvement in PFS was
met at a prespecified interim analysis, but the
data have not yet been disclosed. The phase I/II
trial of ixazomib, lenalidomide, and
dexamethasone in untreated MM
demonstrated an ORR of 92 % with CVGPR in
53 % of patients [73]. Primary treatment-related
toxicities were generally mild and most
commonly were fatigue, rash, nausea,
vomiting, diarrhea, and thrombocytopenia.
Ixazomib is the first oral proteasome inhibitor
to enter phase III testing but additional third
generation proteasome inhibitors including
marizomib and oprozomib have also entered
clinical testing.
Pomalidomide
Pomalidomide is the most potent IMiD and
demonstrates significant activity even in
lenalidomide-refractory patients. Similar to
lenalidomide and thalidomide, pomalidomide
binds to CRBN, and a potential mechanism of
resistance is downregulation of the target.
CRBN expression may be a potential predictive
biomarker for the selection of patients most
likely to respond to pomalidomide, as
pretreatment CRBN levels correspond to the
response to pomalidomide [74]. Pomalidomide
has broad immunomodulatory effects including
T-cell stimulation, inhibition of T regulatory
cells, NK cell activation, enhancement of
antibody-dependent cell-mediated cytotoxicity
(ADCC), and osteoclast inhibition [75].
Thirty-eight relapsed/refractory patients
were initially treated at a continuous dose of
2 mg daily with weekly low-dose
dexamethasone, 63% achieved an objective
response, and a median PFS of 11.6 months
was reported. Grade 3/4 myelotoxicity was the
primary treatment-related toxicity [76]. The
randomized IFM 2009-02 [77] and MM-003
[78] studies both demonstrated the efficacy of
pomalidomide 4 mg on days 1–21 plus
dexamethasone 40 mg weekly, although the
median PFS of 4–5 months was less than the
initial reports. Pomalidomide was granted
accelerated approval in 2013 for patients who
have received at least two prior therapies with
disease progression on or within 60 days of the
previous therapy. The side effect profile is
similar to other IMiDs with a low rate of
sensory neuropathy (10 % all grades) however
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grade 3/4 neutropenia was observed in 47 % of
patients. The safety as well as optimal dosing of
pomalidomide in combination with carfilzomib
and dexamethasone in patients with relapsed/
refractory MM is a current area of investigation
(NCT01665794).
Panobinostat
A number of histone deacetylase inhibitors
(HDACi) have exhibited synergistic
cytotoxicity with bortezomib and may
overcome resistance to proteasome inhibition
through HDACi-induced blockage of the
aggresome pathway, which is a
complementary pathway of intracellular
protein degradation [79]. Single-agent
vorinostat and romidepsin achieve very few
objective responses; however, phase I/II studies
in combination with bortezomib demonstrated
ORR of 20–40 % [80]. The VANTAGE-008 study
was a randomized, phase III study of
bortezomib with or without vorinostat, which
demonstrated no clinically meaningful
improvement in median PFS (7.6 vs.
6.8 months; P = 0.01) but an increased rate of
nausea, vomiting, and fatigue in the vorinostat
group [81]. San-Miguel et al. [100] compared
bortezomib, dexamethasone with or without
panobinostat in a randomized phase III trial of
768 relapsed/refractory MM patients
(PANORAMA-1). A 4-month improvement in
median PFS was seen in the panobinostat group
(12 vs. 8.1 months; HR 0.63; P\0.0001) as well
as an increased rate of CR/nCR (28% vs. 16%;
P = 0.0001), although the ORR was the same
(61% vs. 55%; P = 0.09). The rate of grade 3/4
treatment-related adverse events was higher in
the panobinostat arm, including
thrombocytopenia (67% vs. 31%), diarrhea
(26% vs. 8%), and fatigue (24% vs. 12%).
Panobinostat was approved in 2015 in
combination with bortezomib and
dexamethasone and is the first HDACi
approved for the treatment of MM. HDAC6
selectivity may enhance the potency and reduce
off-target effects compared to non-selective
pan-HDAC inhibitors (vorinostat,
panobinostat) [82]. Ricolinostat (ACY-1215), a
selective HDAC6 inhibitor, is now in clinical
testing in several combinations with other




The next major breakthrough in the therapy of
MM is likely to be the effective incorporation of
monoclonal antibodies. Multiple novel targets
have been identified, and the three agents in
phase III testing include elotuzumab (antiCS-1/
SLAM7) and the anti-CD38 antibodies
daratumumab and SAR650984. Elotuzumab
was tested in combination with bortezomib in
a phase I dose-escalation study and achieved an
ORR of 48% and median PFS of 9.5 months with
no dose-limiting toxicities [83]. Elotuzumab in
combination with lenalidomide and
dexamethasone demonstrated a significant
increase in activity (ORR 82%, CVGPR 29%),
suspected to be due to a synergistic induction of
ADCC-mediated apoptosis [84]. In the recent
phase III study of Rd with or without
elotuzumab (ELOQUENT-2), median PFS was
19.4 vs. 14.9 months in the control group (HR
0.70; P\0.001), and ORR improved to 79% in
the elotuzumab arm versus 66% with Rd
(P\0.001) [85].
Daratumumab demonstrated single-agent
dose-dependent efficacy in a phase I
dose-escalation study with the most common
adverse event of mild infusion-related events,
especially during the initial treatment [86]. ORR
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was 46% in patients treated at the 16 mg/kg
dose level, and no dose-related increase in
adverse effects was observed. In preclinical
studies, lenalidomide enhances the anti-MM
activity of daratumumab [87]. Daratumumab
16 mg/kg plus lenalidomide and
dexamethasone in an expansion cohort
achieved an ORR of 86.7%, and in patients
treated with C6 cycles, VGPR or better was seen
in 64.7% with CR in 11.8% [88]. Most
infusion-related reactions (86%) occurred with
the first infusion, and 18/19 patients were able
to continue the subsequent infusion.
SAR650984 plus lenalidomide and
dexamethasone was evaluated in a phase Ib
trial including heavily pretreated patients with
a median of seven prior therapies (including
pomalidomide and carfilzomib), and an ORR of
63% was achieved with a median PFS of
6.2 months. No dose-limiting toxicities were
observed, and the most common
treatment-related adverse effects were fatigue
(42%), nausea (39%), upper respiratory tract
infection (39%), diarrhea (36%), and
infusion-related reactions in 39%
(predominantly cycle 1). The dose of 10 mg/kg
every 2 weeks was selected for an expansion
cohort [89].
Siltuximab is a chimeric monoclonal
antibody against IL-6 and has been evaluated
as an adjunct to novel agents in the treatment
of MM. In a phase II randomized study of
VMP or VMP plus siltuximab followed by
siltuximab maintenance in newly diagnosed
MM patients, median PFS and 1-year OS were
identical in both arms (17 months and 88%,
respectively), while more hematologic events
and infections occurred in the siltuximab
group [90]. In the relapsed setting, the
addition of siltuximab to bortezomib did not
significantly improve the response rate or PFS
[91].
FUTURE DIRECTIONS
Chimeric antigen T-cell therapy (CAR-T) with
CTL019, an anti-CD19 CAR transduced via
lentiviral vector, is a novel
immunotherapeutic approach currently in
pilot studies in advanced myeloma and holds
promise as a salvage therapy in MM. Further
efforts to stimulate immunity against MM cells
has led to the development of a dendritic
cell-myeloma fusion cell vaccine, which has
been combined with anti-PD-1 antibodies to
stimulate antitumor immunity in the
post-ASCT setting and is currently under
investigation (NCT01067287) [92]. Peptide
vaccines targeting NY-ESO-1 and MAGE-A3 are
also in development. Cell cycle inhibitors
including dinaciclib, an oral cyclin-dependent
kinase inhibitor, and filanesib (ARRY-520), a
kinesin spindle protein inhibitor that arrests
mitosis, both have demonstrated anti-MM
activity in combination with bortezomib and
dexamethasone and are being evaluated in
relapsed disease. Targeting MYC dysregulation
is being explored via CPI-0610, a selective
inhibitor of bromodoman and extra-terminal
protein (BET), which is currently in phase I
testing (NCT02157636). Multiple other
small-molecule inhibitors of deubiquitylating
enzymes (DUBs), the PI3 K/Akt/mTOR pathway,
aurora kinase (MLN8237), and Hedgehog
pathway signaling are undergoing
investigation.
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